Key facts
- BlueCell Bio’s last known valuation is $820K (Aug 2025).
- It has raised $230K; the latest was Early Stage VC ($230K) in Aug 2025.
- Notable investors include Kost, Skarlo.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for BlueCell Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for BlueCell Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BlueCell Bio
Producer of sustainable alternatives intended to replace traditional sources of proteins and fatty acids. The company develops novel fermentation technologies that enhance the bioavailability and sensory qualities of microalgae, enabling clients and users with sustainable, vegan, and nutritious ingredients for food, feed, and pet nutrition.
- Sector
- Healthcare
- HQ
- Frederiksberg, Denmark
- Founded
- 2025
- Employees
- 1
- Website
- bluecell.bio/
- Ownership
- Privately Held (backing)
BlueCell Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BlueCell Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BlueCell Bio in its N-PORT filings yet. We sweep new filings monthly.